GENUS ONCOLOGY - THE MUC1-C COMPANY
Company
Mission
About Us
Genus Overview
Management
Board of Directors
Scientific Advisory Board
Clinical and Research Partners
Contact
Sitemap
Why Target MUC1-C?
Clinical Trials
Summary
GO-203
Phase 2 AML Clinical Trial
The Science
Overview
MUC1 in Human Cancer: The Numbers
MUC1 in Human Cancer: Overexpression
Target for Carcinoma Stem-Like Cell
Target for Leukemia Stem Cell
MUC1-C is an Attractive Target for Reversing Immune Evasion
Intellectual Property
Programs
Pipeline
Targeting the Cytoplasmic Domain
Targeting the Extracellular Domain
Biomarker Program
News & Publications
News
Publications
>
Complete Listing
Role of MUC1-C in Signal Transduction
Role of MUC1-C in Epigenetic Regulation
Role of MUC1-C in Immune Evasion
MUC1 Vaccine
MUC1-C in Stem-like Cells
MUC1-C inhibitor formulated in Nanoparticles
MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
MUC1-C is a druggable target
abstract.jpg
File Size:
2 kb
File Type:
jpg
Download File
abstract-20.jpg
File Size:
1 kb
File Type:
jpg
Download File
Company
Mission
About Us
Genus Overview
Management
Board of Directors
Scientific Advisory Board
Clinical and Research Partners
Contact
Sitemap
Why Target MUC1-C?
Clinical Trials
Summary
GO-203
Phase 2 AML Clinical Trial
The Science
Overview
MUC1 in Human Cancer: The Numbers
MUC1 in Human Cancer: Overexpression
Target for Carcinoma Stem-Like Cell
Target for Leukemia Stem Cell
MUC1-C is an Attractive Target for Reversing Immune Evasion
Intellectual Property
Programs
Pipeline
Targeting the Cytoplasmic Domain
Targeting the Extracellular Domain
Biomarker Program
News & Publications
News
Publications
>
Complete Listing
Role of MUC1-C in Signal Transduction
Role of MUC1-C in Epigenetic Regulation
Role of MUC1-C in Immune Evasion
MUC1 Vaccine
MUC1-C in Stem-like Cells
MUC1-C inhibitor formulated in Nanoparticles
MUC1-C inhibitor is synergistic with chemotherapeutic and targeted drugs
MUC1-C is a druggable target
✕